FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4379798885> ?p ?o ?g. }

• W4379798885 endingPage "1066" @default.
• W4379798885 startingPage "1057" @default.
• W4379798885 abstract "Double-blind randomized controlled trials have compared patients with chronic obstructive pulmonary disease (COPD) taking triple therapy, which can improve lung function, dyspnea, and quality of life and reduce acute exacerbation and mortality, with those taking long-acting muscarinic antagonist/long-acting β2-agonist; however, the real-word treatment scenario may be different from that of a strict and well-designed study. The aim of our study was to assess long-term outcomes among patients with COPD who received triple therapy in real-world practice.Data from Taiwan's National Health Insurance Research Database (NHIRD) from 2005 and 2016 were used to identify COPD patients who were over 40 years of age with diagnosis codes 490-492, 496 (ICD-9-CM) or J41-44 (ICD-10-CM). After matching for age, sex, and COPD exacerbations, COPD patients who did and did not receive triple therapy were enrolled in this study. Cox proportional regression was used to estimate the mortality risk between smoking status and COPD patients with and without triple therapy.A total of 19,358 patients with COPD who did or did not receive triple therapy were enrolled in this study. The prevalence rates of some comorbidities were higher among patients with COPD who received triple therapy than among those who did not receive triple therapy. These comorbidities included lung cancer, thoracic malignancies, bronchiectasis, and heart failure. The risk of mortality was higher among patients who received triple therapy than among those who did not receive triple therapy after matching for age, sex, and COPD exacerbations, with a crude hazard ratio, fully adjusted model hazard ratio and stepwise approach reduced hazard ratio of 1.568 (95% CI, 1.500-1.639), 1.675 (95% CI, 1.596-1.757), and 1.677 (95% CI, 1.599-1.76), respectively.Over 5 years of observation, patients with COPD who received triple therapy did not show a survival benefit compared with those who did not receive triple therapy in a real-world scenario." @default.
• W4379798885 created "2023-06-09" @default.
• W4379798885 creator A5032122455 @default.
• W4379798885 creator A5076533674 @default.
• W4379798885 creator A5078020190 @default.
• W4379798885 date "2023-06-01" @default.
• W4379798885 modified "2023-10-15" @default.
• W4379798885 title "Real-World Experience of Treating Chronic Obstructive Pulmonary Disease with Triple Therapy" @default.
• W4379798885 cites W1853608828 @default.
• W4379798885 cites W1930304162 @default.
• W4379798885 cites W201724846 @default.
• W4379798885 cites W2029770479 @default.
• W4379798885 cites W2064899799 @default.
• W4379798885 cites W2124721775 @default.
• W4379798885 cites W2127951128 @default.
• W4379798885 cites W2159477321 @default.
• W4379798885 cites W2164945400 @default.
• W4379798885 cites W2344148139 @default.
• W4379798885 cites W2513086234 @default.
• W4379798885 cites W2604577460 @default.
• W4379798885 cites W2604743750 @default.
• W4379798885 cites W2785999277 @default.
• W4379798885 cites W2802221596 @default.
• W4379798885 cites W2810478122 @default.
• W4379798885 cites W2955803684 @default.
• W4379798885 cites W3003762148 @default.
• W4379798885 cites W3037411127 @default.
• W4379798885 cites W3118667696 @default.
• W4379798885 cites W3200595183 @default.
• W4379798885 cites W4200009045 @default.
• W4379798885 cites W4211263216 @default.
• W4379798885 doi "https://doi.org/10.2147/copd.s404039" @default.
• W4379798885 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37309394" @default.
• W4379798885 hasPublicationYear "2023" @default.
• W4379798885 type Work @default.
• W4379798885 citedByCount "0" @default.
• W4379798885 crossrefType "journal-article" @default.
• W4379798885 hasAuthorship W4379798885A5032122455 @default.
• W4379798885 hasAuthorship W4379798885A5076533674 @default.
• W4379798885 hasAuthorship W4379798885A5078020190 @default.
• W4379798885 hasBestOaLocation W43797988851 @default.
• W4379798885 hasConcept C126322002 @default.
• W4379798885 hasConcept C168563851 @default.
• W4379798885 hasConcept C1862650 @default.
• W4379798885 hasConcept C2776256026 @default.
• W4379798885 hasConcept C2776780178 @default.
• W4379798885 hasConcept C2777014857 @default.
• W4379798885 hasConcept C2777714996 @default.
• W4379798885 hasConcept C2779379686 @default.
• W4379798885 hasConcept C71924100 @default.
• W4379798885 hasConceptScore W4379798885C126322002 @default.
• W4379798885 hasConceptScore W4379798885C168563851 @default.
• W4379798885 hasConceptScore W4379798885C1862650 @default.
• W4379798885 hasConceptScore W4379798885C2776256026 @default.
• W4379798885 hasConceptScore W4379798885C2776780178 @default.
• W4379798885 hasConceptScore W4379798885C2777014857 @default.
• W4379798885 hasConceptScore W4379798885C2777714996 @default.
• W4379798885 hasConceptScore W4379798885C2779379686 @default.
• W4379798885 hasConceptScore W4379798885C71924100 @default.
• W4379798885 hasLocation W43797988851 @default.
• W4379798885 hasLocation W43797988852 @default.
• W4379798885 hasLocation W43797988853 @default.
• W4379798885 hasOpenAccess W4379798885 @default.
• W4379798885 hasPrimaryLocation W43797988851 @default.
• W4379798885 hasRelatedWork W2163918855 @default.
• W4379798885 hasRelatedWork W2565093911 @default.
• W4379798885 hasRelatedWork W2605886686 @default.
• W4379798885 hasRelatedWork W2766959490 @default.
• W4379798885 hasRelatedWork W2776194147 @default.
• W4379798885 hasRelatedWork W2781208394 @default.
• W4379798885 hasRelatedWork W2794167087 @default.
• W4379798885 hasRelatedWork W2912535772 @default.
• W4379798885 hasRelatedWork W3001214709 @default.
• W4379798885 hasRelatedWork W4207014058 @default.
• W4379798885 hasVolume "Volume 18" @default.
• W4379798885 isParatext "false" @default.
• W4379798885 isRetracted "false" @default.
• W4379798885 workType "article" @default.